Shots:
- The P-IIIb SEAVUE study involves assessing Stelara(6 mg/kg, IV at baseline, then 90mg, SC, q8w) vs Humira (160/80mg, SC at baseline, then 40mg, SC, q2w) in the treatment of 386 biologic-naïve patients in a ratio (1:1) with mod. to sev. active CD
- The data demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response, and endoscopic response through 1yr., although the 1EPs of statistical superiority was not demonstrated
- Additional abstracts of data are also being presented at DDW, which include safety of Stelara in IBD along with long term data of Stelara in the IM-UNITI study with RWE of the therapy for CD
Click here to read full press release/ article | Ref: J&J | Image: Ars Technica
The post Janssen’s Stelara Fails to Show Superiority over AbbVie’s Humira in P-IIIb SEAVUE Study for Crohn’s Disease, Presented at DDW 2021 first appeared on PharmaShots.
